Pharmacokinetics and its role in small molecule drug discovery research

被引:82
作者
Jang, GR [1 ]
Harris, RZ [1 ]
Lau, DT [1 ]
机构
[1] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
关键词
pharmacokinetics; noncompartmental pharmacokinetics; compartmental pharmacokinetics; drug discovery; ADME;
D O I
10.1002/med.1015
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Pharmacokinetics (PK), which describes the disposition of a drug in the body, should be a primary consideration in the selection of a drug candidate, ultimately contributing to its eventual clinical success or failure. Accordingly, a sound understanding of PK concepts and an appreciation of the judicious use of PK and related (e.g., metabolism, transporter) data in drug discovery can be beneficial to those involved in the process. This review defines important PK parameters (e.g., clearance, volume of distribution, half-life), describes methods of PK data analysis (noncompartmental vs. compartmental) and provides an overview of additional concepts such as allometric scaling, PK/pharmacodynamic modeling, and nonlinear PK. Furthermore, the role and strategic use of PK screens in drug discovery are discussed. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:382 / 396
页数:15
相关论文
共 7 条
[1]
Benet L., 1996, The pharmacological basis of therapeutics, V9th, P3
[2]
FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES [J].
BOXENBAUM, H ;
DILEA, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :957-966
[3]
Calabrese E., 1991, PRINCIPLES ANIMAL EX
[4]
GIBALDI M, 1993, PHARMACOKINETICS
[5]
Role of drug metabolism in drug discovery and development [J].
Kumar, GN ;
Surapaneni, S .
MEDICINAL RESEARCH REVIEWS, 2001, 21 (05) :397-411
[6]
LAVENDHOMME R, 1996, KLUW T MATH, V13, P1
[7]
ROWLAND M, 1991, CLIN PHARMACOKINETIC